Chemotherapy-Induced Peripheral Neuropathy Impacts Quality of Life and Activities of Daily Living of Brazilian Multiple Myeloma Patients

Title:Chemotherapy-Induced Peripheral Neuropathy Impacts Quality of Life and Activities of Daily Living of Brazilian Multiple Myeloma Patients

Volume: 19 Issue: 3

Author(s): Paula Lana de Miranda Drummond*, Roberta Márcia Marques dos Santos, Lívia Pena Silveira, Jéssica Soares Malta, Adriano Max Moreira Reis, Naiane Lima Costa, Roberta Oliveira de Paula e Silva, Evandro Maranhão Fagundes and Cristiane Aparecida Menezes de Pádua

Affiliation:

• Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
• Ezequiel Dias Foundation, Regulatory Affairs, Belo Horizonte, Brazil

Keywords: Peripheral neuropathy, health-related quality of life, multiple myeloma, thalidomide, bortezomib, drug safety.

Abstract:

Background: Survival in multiple myeloma (MM) has improved in the past years with the introduction of immunomodulators and proteasome inhibitors. However, chemotherapyinduced peripheral neuropathy (CIPN) is associated with both drug classes affecting Health- Related Quality of Life (HRQoL) and activities of daily living (ADL).

Objective: We evaluated CIPN in MM patients to identify associated factors and impacts on HRQoL and ADL.

Methods: This is a cross-sectional study with Brazilian patients from public and private health services. Patients were interviewed using validated tools to measure CIPN and HRQoL, along with sociodemographic and clinical questions. Logistic regression was used to assess the association of CIPN with sociodemographic, clinical, and HRQoL variables.

Results: In total, 217 patients were eligible for the study. The median age was 67, 50.9% were women, 51.6% had low income, 47.5% had low education, and 55.3% attended private health services. The chemotherapy regimen most used was the combination of cyclophosphamide, thalidomide, and dexamethasone (17.5%) among the 24 types of regimens found. Most patients (90.3%) had at least one CIPN symptom: 62.7% were severe, and 51.62% were extremely bothered ADL. Numbness was the most common symptom (40.6%). CIPN was independently associated with education, hospitalization, chemotherapy, side effects, disease symptoms, and global health status in HRQoL.

Conclusion: MM patients showed a high frequency of CIPN, which affected ADL and impaired HRQoL. Early and accurate detection of CIPN and dose management in patients with thalidomide and bortezomib-based regimens should be performed to provide better treatment outcomes and avoid permanent disabilities.

Cite this article as:

de Miranda Drummond Lana Paula*, dos Santos Márcia Marques Roberta, Silveira Pena Lívia, Malta Soares Jéssica, Moreira Reis Max Adriano, Costa Lima Naiane, de Paula e Silva Oliveira Roberta, Fagundes Maranhão Evandro and de Pádua Menezes Cristiane Aparecida, Chemotherapy-Induced Peripheral Neuropathy Impacts Quality of Life and Activities of Daily Living of Brazilian Multiple Myeloma Patients, Current Drug Safety 2024; 19 (3) . https://dx.doi.org/10.2174/1574886318666230817162424